FDA: Spiriva HandiHaler doesn't increase stroke or heart risks

01/14/2010 | Wall Street Journal, The

The FDA concluded that clinical data show no concrete evidence that Spiriva HandiHaler heightens the risk of stroke or cardiovascular problems in patients with chronic obstructive pulmonary disease. The product, which is owned by Boehringer Ingelheim and Pfizer, underwent a government investigation in 2008 because of stroke concerns.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Executive Medical Director
Aspirus Network Inc
Wausau, WI